期刊文献+

细胞因子在清肝化瘀汤治疗慢性粒细胞性白血病中的研究 被引量:3

Study of cytokines on Qingganhuayu decoction in treatment of chronic myeloid leukemia
下载PDF
导出
摘要 目的 观察中药清肝化瘀汤治疗慢性粒细胞性白血病 (慢性期 )的疗效 ,并探讨细胞因子水平变化的意义。方法 收集 45例慢性粒细胞性白血病慢性期患者 (治疗组 ) ,用清肝化瘀汤治疗 ,观察患者的临床疗效、细胞因子水平。另用 2 0名正常人作为对照 (对照组 )。结果 治疗组完全缓解率 40 % ,部分缓解率 46 .7% ,总有效率 86 .7%。治疗组细胞因子水平中白介素 2、可溶性白介素 2受体、肿瘤坏死因子α治疗前后有显著差异 (P <0 .0 5 ) ;干扰素γ水平变化无显著差异。且与正常对照组比较无显著差异 (P >0 .0 5 )。结论 清肝化瘀汤有清热泻肝解毒、活血化瘀消疒徵 的功效 ,研究结果显示 ,该药对慢性粒细胞性白血病慢性期 (肝热血瘀型 )疗效确切 ,其作用机理可能与改善细胞因子水平有关。 Objective To observe the therapeutic effect of Qingganhuayu decoction on Chronic Myeloid Leukemia and the changes of cytokines level. Method By observing the clinical efficacy and changes of cytokines level in 45 patients with CML. Results In the treatment group, complete remission rate(CR)was 40%,partial remission rate(PR)was 46.7%, the total effective rate was 86.7%. There were changes in the level of IL 2,sIL 2R,and TNF α ( P <0.05),but not IFN γ( P >0.05). Conclusion Qingganhuayu decoction is effective for CML. (Shanghai Med J, 2001,24∶161)
作者 邱仲川 徐旻
出处 《上海医学》 CAS CSCD 北大核心 2001年第3期161-162,155,共3页 Shanghai Medical Journal
关键词 中医药治疗 慢性粒细胞性白血病 临床研究 细胞因子 清肝化瘀汤 Herb decoction Chronic myeloid leukemia Clinical study Cytokine
  • 相关文献

参考文献3

二级参考文献33

共引文献36

同被引文献18

  • 1马军,王建祥,主编.造血系统疾病临床诊疗规范教程[M].北京:北京大学医学出版社,2009:548.
  • 2中华人民共和国卫生部.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.115-119.
  • 3梁冰,葛志红.血液科专病中医临床诊治[M].2版.北京:人民卫生出版社,2005:235-237.
  • 4Hoessel R,Leclerc S,Endicott J A,et al.Indirubin,the active constit-uent of a Chinese antileukaemia medicine,inhibits cyclin dependent kinases[J].Nat Cell Biol,1999,5(1):60-67.
  • 5Marko D,Schatzle S,Friedel A,et al.Inhibition of cyclin dependent kinase1(CDK1)by indirubin derivatives in human tumourcells[J].Br J Cancer,2001,84(2):283-289.
  • 6Choi SJ,MoonM J,Lee SD,et al.Indirubin derivatives as potent FLT3 inhibitorswith anti proliferative activity of acutemyeloid leukemic cells[J].Bioorg Med Chem Lett,2010,20(6):2033-2037.
  • 7Miller AB,Hoogstraten B,Staquet M,et al.Reporting results of cancer treatment[J].Cancer,1981,47:207.
  • 8Petti MC,Spadea A,Avvisati G,et al.Polycythemia vera treated with pipobroman as single agent:low incidence of secondary leukemiain a cohort of patients observed during20years(1971-1991)[J].Leukemia,1998,12(6):869.
  • 9Vanlet P, Horny HP, Bennet JM, et al. Definitions and standards in the diagnosis and treatment of myelodysplatic syndromes : Con- sensus statements and report from a working conference[ J ]. Leuk Res,2007,31 : 727 -736.
  • 10Greenberg P, Cox C, LeBeau MM, et al. International senring sys- tem for evaluating prognosis in myelodysplestic syndromes [ J ]. Blood,1997,89 : 2079 - 2088.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部